These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36593066)

  • 41. The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus.
    Cazzato G; Cascardi E; Colagrande A; Lettini T; Resta L; Bizzoca C; Arezzo F; Loizzi V; Dellino M; Cormio G; Casatta N; Lupo C; Scillimati A; Scacco S; Parente P; Lospalluti L; Ingravallo G
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A case of primary malignant melanoma of the esophagus with a widely expanded surface area.
    Nakamura K; Urabe Y; Oka S; Ito M; Kotachi T; Ninomiya Y; Boda T; Hiyama T; Emi M; Hamai Y; Shiroma N; Tanaka S; Chayama K
    Clin J Gastroenterol; 2019 Oct; 12(5):424-428. PubMed ID: 30887427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary amelanotic malignant melanoma of the esophagus: a case report.
    Koga N; Kubo N; Saeki H; Sasaki S; Jogo T; Hirose K; Nakashima Y; Oki E; Koga Y; Oda Y; Oiwa H; Oiwa T; Maehara Y
    Surg Case Rep; 2019 Jan; 5(1):4. PubMed ID: 30635729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review.
    Zhao T; Kong FW; Wang H; Liu D; Wang CY; Luo JH; Zhang M; Wu WB
    Medicine (Baltimore); 2017 May; 96(21):e7003. PubMed ID: 28538413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radical Resection in an Era of Immune Therapy for Primary Esophageal Melanoma.
    Williams E; Bolger JC; Darling G
    Ann Thorac Surg; 2022 Dec; 114(6):e423-e425. PubMed ID: 35218701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case.
    Imai S; Suzuki A; Yamamoto Y; Koyama M; Sugiyama S; Kitazawa M; Miyagawa Y; Miyagawa S
    Clin J Gastroenterol; 2017 Aug; 10(4):336-341. PubMed ID: 28550655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary malignant melanoma of the esophagus treated with subtotal esophagectomy: a case report.
    Kuwabara S; Ebihara Y; Nakanishi Y; Asano T; Noji T; Kurashima Y; Murakami S; Nakamura T; Tsuchikawa T; Okamura K; Shichinohe T; Hirano S
    BMC Surg; 2017 Dec; 17(1):122. PubMed ID: 29197361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary Malignant Melanoma of the Esophagus in a 76-Year-Old Female.
    Kashfi S; Marneni N; Sharma S; Vigoda I
    Cureus; 2022 Mar; 14(3):e23250. PubMed ID: 35449629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Primary malignant melanoma of the esophagus--detection of circulating tumor cells].
    Fujii K; Goto A; Matsunaga Y; Hasegawa Y; Sukawa Y; Suzuki K; Yonezawa K; Abe T; Itoh A; Shinomura Y; Iimura Y; Hasegawa N; Nakamura H; Yoshida Y
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1539-43. PubMed ID: 20716882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
    Bai X; Shoushtari AN; Betof Warner A; Si L; Tang B; Cui C; Yang X; Wei X; Quach HT; Cann CG; Zhang MZ; Pallan L; Harvey C; Kim MS; Kasumova G; Sharova T; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Frederick DT; Flaherty KT; Long GV; Menzies AM; Sullivan RJ; Boland GM; Johnson DB; Guo J
    Br J Dermatol; 2022 Sep; 187(3):401-410. PubMed ID: 35293617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
    Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV
    Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.